Distinct parameters of the basophil activation test reflect the severity and threshold of allergic reactions to peanut.

Abstract

BACKGROUND:

The management of peanut allergy relies on allergen avoidance and epinephrine autoinjector for rescue treatment in patients at risk of anaphylaxis. Biomarkers of severity and threshold of allergic reactions to peanut could significantly improve the care for patients with peanut allergy.

OBJECTIVE:

We sought to assess the utility of the basophil activation test (BAT) to predict the severity and threshold of reactivity to peanut during oral food challenges (OFCs).

METHODS:

The severity of the allergic reaction and the threshold dose during OFCs to peanut were determined. Skin prick tests, measurements of specific IgE to peanut and its components, and BATs to peanut were performed on the day of the challenge.

RESULTS:

Of the 124 children submitted to OFCs to peanut, 52 (median age, 5 years) reacted with clinical symptoms that ranged from mild oral symptoms to anaphylaxis. Severe reactions occurred in 41% of cases, and 57% reacted to 0.1 g or less of peanut protein. The ratio of the percentage of CD63(+) basophils after stimulation with peanut and after stimulation with anti-IgE (CD63 peanut/anti-IgE) was independently associated with severity (P = .001), whereas the basophil allergen threshold sensitivity CD-sens (1/EC₅₀ × 100, where EC₅₀ is half maximal effective concentration) value was independently associated with the threshold (P = .020) of allergic reactions to peanut during OFCs. Patients with CD63 peanut/anti-IgE levels of 1.3 or greater had an increased risk of severe reactions (relative risk, 3.4; 95% CI, 1.8-6.2). Patients with a CD-sens value of 84 or greater had an increased risk of reacting to 0.1 g or less of peanut protein (relative risk, 1.9; 95% CI, 1.3-2.8).

CONCLUSIONS:

Basophil reactivity is associated with severity and basophil sensitivity is associated with the threshold of allergic reactions to peanut. CD63 peanut/anti-IgE and CD-sens values can be used to estimate the severity and threshold of allergic reactions during OFCs.

• Authors: Alexandra F Santos, George Du Toit, Abdel Douiri, Suzana Radulovic, Alick Stephens, Victor Turcanu, Gideon Lack
• Journal: The Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 135 Issue 1 Pg. 179-86 (Jan 2015) ISSN: 1097-6825 [Electronic] United States
• PMID: 25567046 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Chemical References

• CD63 protein, human
• Tetraspanin 30
• Immunoglobulin E

Topics

• Adolescent
• Arachis (adverse effects, immunology)
• Basophils (immunology)
• Child
• Child, Preschool
• Female
• Humans
• Immunoglobulin E (blood)
• Immunologic Tests
• Infant
• Male
• Peanut Hypersensitivity (blood, diagnosis, immunology)
• Severity of Illness Index
• Tetraspanin 30 (immunology)